Sandra J. Horning

Supplementary Data from Expression of p21 Protein Predicts Clinical Outcome in DLBCL Patients Older than 60 Years Treated with R-CHOP but not CHOP: A Prospective ECOG and Southwest Oncology Group Correlative Study on E4494

Jane N. Winter, Shuli Li, Vikas Aurora, Daina Variakojis et autres

Supplementary Data from Expression of p21 Protein Predicts Clinical Outcome in DLBCL Patients Older than 60 Years Treated with R-CHOP but not CHOP: A Prospective ECOG and Southwest Oncology Group Correlative Study on E4494

Supplementary Data from Expression of p21 Protein Predicts Clinical Outcome in DLBCL Patients Older than 60 Years Treated with R-CHOP but not CHOP: A Prospective ECOG and Southwest Oncology Group Correlative Study on E4494

Jane N. Winter, Shuli Li, Vikas Aurora, Daina Variakojis et autres

Supplementary Data from Expression of p21 Protein Predicts Clinical Outcome in DLBCL Patients Older than 60 Years Treated with R-CHOP but not CHOP: A Prospective ECOG and Southwest Oncology Group Correlative Study on E4494

Supplementary Material from Developing Standards for Breakthrough Therapy Designation in Oncology

Sandra J. Horning, Daniel A. Haber, Wendy K. D. Selig, S. Percy Ivy et autres

Supplementary Material: Case Studies of Recent Therapeutic Breakthroughs PDF file 98K, This describes four recent breakthroughs (3 in oncology and 1 in cystic fibrosis)

Related Article from Developing Standards for Breakthrough Therapy Designation in Oncology

Sandra J. Horning, Daniel A. Haber, Wendy K. D. Selig, S. Percy Ivy et autres

Related Article from Developing Standards for Breakthrough Therapy Designation in Oncology

Data from Expression of p21 Protein Predicts Clinical Outcome in DLBCL Patients Older than 60 Years Treated with R-CHOP but not CHOP: A Prospective ECOG and Southwest Oncology Group Correlative Study on E4494

Jane N. Winter, Shuli Li, Vikas Aurora, Daina Variakojis et autres

Abstract Purpose: To prospectively investigate the prognostic significance of p21 and p53 expression in diffuse large B-cell lymphoma in the context of the U.S. Intergroup trial comparing conventional cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy to rituximab-CHOP (R-CHOP) induction, with or without …

Data from Developing Standards for Breakthrough Therapy Designation in Oncology

Sandra J. Horning, Daniel A. Haber, Wendy K. D. Selig, S. Percy Ivy et autres

Abstract In July 2012, Congress passed the Food and Drug Administration Safety and Innovation Act (FDASIA). The Advancing Breakthrough Therapies for Patients Act was incorporated into a Title of FDASIA to expedite clinical development of new, potential “breakthrough” drugs or treatments that …

Data from Expression of p21 Protein Predicts Clinical Outcome in DLBCL Patients Older than 60 Years Treated with R-CHOP but not CHOP: A Prospective ECOG and Southwest Oncology Group Correlative Study on E4494

Jane N. Winter, Shuli Li, Vikas Aurora, Daina Variakojis et autres

Abstract Purpose: To prospectively investigate the prognostic significance of p21 and p53 expression in diffuse large B-cell lymphoma in the context of the U.S. Intergroup trial comparing conventional cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy to rituximab-CHOP (R-CHOP) induction, with or without …

Data from Developing Standards for Breakthrough Therapy Designation in Oncology

Sandra J. Horning, Daniel A. Haber, Wendy K. D. Selig, S. Percy Ivy et autres

Abstract In July 2012, Congress passed the Food and Drug Administration Safety and Innovation Act (FDASIA). The Advancing Breakthrough Therapies for Patients Act was incorporated into a Title of FDASIA to expedite clinical development of new, potential “breakthrough” drugs or treatments that …

Related Article from Developing Standards for Breakthrough Therapy Designation in Oncology

Sandra J. Horning, Daniel A. Haber, Wendy K. D. Selig, S. Percy Ivy et autres

Related Article from Developing Standards for Breakthrough Therapy Designation in Oncology

Supplementary Material from Developing Standards for Breakthrough Therapy Designation in Oncology

Sandra J. Horning, Daniel A. Haber, Wendy K. D. Selig, S. Percy Ivy et autres

Supplementary Material: Case Studies of Recent Therapeutic Breakthroughs PDF file 98K, This describes four recent breakthroughs (3 in oncology and 1 in cystic fibrosis)

Incorporation of extracorporeal photopheresis into a reduced intensity conditioning regimen in myelodysplastic syndrome and aggressive lymphoma: results from ECOG 1402 and 1902

Francine M. Foss, Victoria Wang, Selina M. Luger, Opeyemi A. Jegede et autres

BACKGROUND: Extracorporeal photopheresis (ECP) is an immunomodulatory cellular therapy which has been shown to induce a tolerogenic state in patients with acute and chronic graft-vs-host disease. ECOG-ACRIN explored the activity of ECP as a part of a reduced intensity conditioning regimen in …

us, ca (code pays fourni par la source)

Follicular lymphoma patients with KIR2DL2 and KIR3DL1 and their ligands (HLA-C1 and HLA-Bw4) show improved outcome when receiving rituximab

Amy K. Erbe, Wei Wang, Lakeesha L. Carmichael, Anna Hoefges et autres

BACKGROUND: The ECOG-ACRIN Cancer Research Group evaluated rituximab treatment schedules for patients with newly-diagnosed low-tumor-burden follicular-lymphoma (FL). All patients received 4-weekly rituximab treatments as induction therapy. Clinically-responding patients were randomized to receive rituximab every 13 weeks ("maintenance") vs. no additional rituximab until …

us, ca (code pays fourni par la source)